Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Article

Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL

Joshua A. Bauer, Douglas K. Trask, Bhavna Kumar, Gerrit Los, Jason Castro, Julia Shin-Jung Lee, Jianyong Chen, Shaomeng Wang, Carol R. Bradford and Thomas E. Carey
Joshua A. Bauer
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Douglas K. Trask
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bhavna Kumar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerrit Los
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason Castro
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Shin-Jung Lee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jianyong Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaomeng Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carol R. Bradford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas E. Carey
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.MCT-05-0081 Published July 2005
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: July 2005 to January 2021

AbstractFull-text HTMLPDF
Total354136362277

Cited By

Article Information

Volume 4, Issue 7, pp. 1096-1104

DOI 
https://doi.org/10.1158/1535-7163.MCT-05-0081
PubMed 
16020667

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • May 4, 2005
  • March 21, 2005
  • April 27, 2005
  • Published first July 14, 2005.

Copyright & Usage 
American Association for Cancer Research

Author Information

  1. Joshua A. Bauer1,
  2. Douglas K. Trask2,
  3. Bhavna Kumar2,
  4. Gerrit Los6,
  5. Jason Castro2,
  6. Julia Shin-Jung Lee45,
  7. Jianyong Chen3,
  8. Shaomeng Wang35,
  9. Carol R. Bradford25 and
  10. Thomas E. Carey125
  1. Departments of 1Pharmacology, 2Otolaryngology-Head and Neck Surgery, and 3Internal Medicine and Medicinal Chemistry; 4Biostatistics Unit; and 5University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan; and 6Pfizer Global Research and Development, La Jolla, California
  1. Requests for reprints: Thomas E. Carey, Department of Otolaryngology, University of Michigan, 6020 KHRI, 1301 East Ann Street, Ann Arbor, MI 48109-0506. Phone: 734-764-4371; Fax: 734-764-0014. E-mail: careyte{at}umich.edu
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 4 (7)
July 2005
Volume 4, Issue 7
  • Table of Contents
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL
Joshua A. Bauer, Douglas K. Trask, Bhavna Kumar, Gerrit Los, Jason Castro, Julia Shin-Jung Lee, Jianyong Chen, Shaomeng Wang, Carol R. Bradford and Thomas E. Carey
Mol Cancer Ther July 1 2005 (4) (7) 1096-1104; DOI: 10.1158/1535-7163.MCT-05-0081

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL
Joshua A. Bauer, Douglas K. Trask, Bhavna Kumar, Gerrit Los, Jason Castro, Julia Shin-Jung Lee, Jianyong Chen, Shaomeng Wang, Carol R. Bradford and Thomas E. Carey
Mol Cancer Ther July 1 2005 (4) (7) 1096-1104; DOI: 10.1158/1535-7163.MCT-05-0081
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers
  • Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non–small cell lung cancer cells (H1299)
  • Identification of a small topoisomerase I–binding peptide that has synergistic antitumor activity with 9-aminocamptothecin
Show more Article
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement